SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-009838
Filing Date
2021-03-01
Accepted
2021-03-01 16:02:54
Documents
14
Period of Report
2021-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K - FINANCIAL UPDATE tptx-8k_20210301.htm   iXBRL 8-K 38696
2 EX-99.1 tptx-ex991_65.htm EX-99.1 292821
3 GRAPHIC gwj0vubapcvu000001.jpg GRAPHIC 20841
  Complete submission text file 0001564590-21-009838.txt   508483

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tptx-20210301.xsd EX-101.SCH 5800
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tptx-20210301_lab.xml EX-101.LAB 19480
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tptx-20210301_pre.xml EX-101.PRE 11650
7 EXTRACTED XBRL INSTANCE DOCUMENT tptx-8k_20210301_htm.xml XML 3576
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

IRS No.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38871 | Film No.: 21697630
SIC: 2834 Pharmaceutical Preparations